Get the Stockscreener App
0.32
5.19%
-0.0175
Pre-market:
.34
0.02
+6.25%
Curanex Pharmaceuticals Inc stock is traded at $0.32, with a volume of 85,014.
It is down -5.19% in the last 24 hours and up +6.56% over the past month.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
See More
Previous Close:
$0.3375
Open:
$0.32
24h Volume:
85,014
Relative Volume:
0.60
Market Cap:
$9.08M
Revenue:
-
Net Income/Loss:
$-7.24M
P/E Ratio:
-1.2529
EPS:
-0.2554
Net Cash Flow:
$-11.29M
1W Performance:
+4.75%
1M Performance:
+6.56%
6M Performance:
-21.16%
1Y Performance:
+0.00%
1-Day Range:
$0.32
$0.3314
1-Week Range:
$0.3001
$0.36
52-Week Range:
$0.262
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Name
Curanex Pharmaceuticals Inc
Sector
Industry
Phone
718-673-6078
Address
2 JERICHO PLAZA,, JERICHO
Compare CURX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.32 | 9.57M | 0 | -7.24M | -11.29M | -0.2554 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curanex Pharmaceuticals Inc Stock (CURX) Latest News
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curanex Stock Sinks Toward 31 Cents as Nasdaq Clock Ticks - Bez Kabli
Curanex Pharmaceuticals Inc (CURX) Sees Modest Gain as Shares Test Key LevelsTechnical Analysis Picks - The Legal Advocate
Curanex Pharmaceuticals Inc. Faces Investigation Over Securities Fraud - GuruFocus
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Weekly Voice
Investigation launched into potential securities fraud at Curanex Pharmaceuticals after volatile stock plunge. - Pluang
Curanex Pharmaceuticals Inc. Q1 2026 10-Q Report: Financials, Growth Strategy & Pipeline Expansion - minichart.com.sg
Curanex completes manufacturing, toxicology work for ulcerative colitis drug - Investing.com UK
Curanex completes manufacturing, toxicology work for ulcerative colitis drug By Investing.com - Investing.com South Africa
CURX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Curanex Advances Phyto-N Program and Expands Indications - TipRanks
Curanex Pharmaceuticals Advances Phyto-N Toward FDA Submission for Ulcerative Colitis and Expands Pipeline to Cancer Cachexia - Minichart
Curanex Pharmaceuticals advancing phyto-n toward a planned investigational new drug submission to FDA for ulcerative colitis in Q4 2026 - marketscreener.com
Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia - Stock Titan
Curanex Pharmaceuticals Advances Toward Q4 2026 IND Submission for Ulcerative Colitis and Expands Pipeline to Include Cancer Cachexia - Quiver Quantitative
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission - The Manila Times
Curanex Pharmaceuticals Inc 1Q 2026: Net income $(3.15M), EPS $(0.11) — 10-Q Summary - TradingView
Curanex (NASDAQ: CURX) ramps Phyto-N R&D as Nasdaq listing faces bid-price deadline - Stock Titan
TradingKey - TradingKey
Curanex awaits quarterly results as investors monitor for potential updates, CURX shares steady in quiet trading session.Investment Signal Network - newser.com
Is Curanex (CURX) a once in a decade opportunity? (Volatility Increases) 2026-05-08Stock News - newser.com
Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance - Investing.com Nigeria
Curanex Granted Nasdaq Extension to Regain Listing Compliance - TipRanks
Curanex Pharmaceuticals given second Nasdaq bid-price compliance period through Nov. 2, 2026 - TradingView
[8-K] Curanex Pharmaceuticals Inc Reports Material Event - Stock Titan
Get insights into the top gainers and losers of Tuesday's after-hours session. - ChartMill
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with ... - Caledonian Record
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm - GlobeNewswire
CURX Ownership | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill
CURANEX PHARMACEUTICALS INC (CURX) Fundamental Analysis & Valuation - ChartMill
Curanex (CURX) Stock: What Is Driving the Price (Momentum Building) 2026-04-20Real Time Stock Idea Network - UBND thành phố Hải Phòng
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX - The Joplin Globe
These stocks are moving in today's pre-market session - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Exclusive: Penny stock Curanex expands cachexia focus backed by patient recovery narratives - MSN
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases - MSN
Curanex Pharmaceuticals Inc (CURX) stock price, news, quote and history - Yahoo Finance Singapore
Curanex Pharmaceuticals Inc (CURX) Latest Stock News & Headlines - Yahoo Finance
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline - The Manila Times
Curanex Pharmaceuticals Reports Positive Patient Outcomes in Advanced Cancer and Critical Illness Cases Following Use of Lead Product - Quiver Quantitative
Five critically ill patient accounts inform Curanex's cachexia focus - Stock Titan
EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care - The Manila Times
Curanex Pharmaceuticals Highlights Patient Case Supporting Phyto-N's Potential in Cancer Cachexia Treatment - Quiver Quantitative
One cancer patient kept working 2+ years in Curanex Phyto-N case - Stock Titan
Curanex Pharmaceuticals Inc Stock (CURX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):